Background: Intramuscular (IM) ziprasidone is often used to manage acute agitation. Limited data exist on the pediatric dosing of ziprasidone in the emergency department (ED). Objective: To characterize the mg/kg dosing differences between pediatric ED patients who respond to an initial dose of ziprasidone versus patients who do not. Methods: This was a retrospective, observational study of 5-to 18-year-old patients who were treated with IM ziprasidone in the pediatric ED from 2007 to 2015. Medical records were reviewed to determine demographic and clinical information. Patients were deemed responders to ziprasidone if they required no additional rescue medication for acute agitation within 30 minutes of the initial dose. Results: Forty children received 50 doses of IM ziprasidone. Twenty-seven (68%) patients responded to the initial ziprasidone dose, requiring no further medication intervention for their acute agitation. Responders were given a mean initial dose of 0.19 + 0.1 mg/kg, while nonresponders were given an initial mean dose of 0.13 + 0.06 mg/kg (P ¼ .03). Conclusion: A significant dose difference exists between patients who required only one initial dose of ziprasidone compared to those who required additional medication. As a result, an initial dose of 0.2 mg/kg of IM ziprasidone may be considered when managing acutely agitated pediatric patients in the ED.
Introduction
Pediatric psychiatric-related visits account for 3.3% of the 30 million pediatric emergency department (ED) visits occurring each year. 1 As a result, pediatric EDs increasingly bear the burden of managing acutely agitated psychiatric patients in a nonpsychiatric setting. Quick management of these patients' agitated episodes is imperative for the safety of the patient and the health-care provider. When patients are not able to be redirected through psychosocial interventions, intramuscular (IM) injections of atypical antipsychotics have shown substantial efficacy in the treatment of aggression in select pediatric populations. 2, 3 Atypical antipsychotics such as ziprasidone, olanzapine, and risperidone are preferred over typical antipsychotics and benzodiazepines due to their reduced risk of extrapyramidal symptom (EPS) and disinhibiting effects. IM ziprasidone is often chosen due its relatively quick onset and half-life of 2 to 5 hours, thus making it a favorable agent. 4, 5 Common adverse effects include somnolence and dizziness. More serious adverse effects include QT prolongation, EPS, and neuroleptic malignant syndrome.
Only 5 publications evaluate the use of IM ziprasidone in acutely agitated pediatric patients. [6] [7] [8] [9] [10] All were retrospective and performed in a psychiatric facility-none evaluated pediatric patients in the ED. Dosing was also inconsistent between the studies. Ten and 20 mg doses were administered without consideration of the patient's weight. As pediatric psychiatric emergencies become more prevalent in EDs, it is important for clinicians to identify safe and effective dosing parameters for such patients.
Methods

Study Design and Objectives
This was a retrospective, observational study of patients 5 to 18 years of age who were treated with IM ziprasidone in the pediatric ED at Virginia Commonwealth University, a tertiary academic medical center. The study underwent expedited approval by the institutional review board.
The primary objective of the study was to characterize the difference in dose between IM ziprasidone responders and nonresponders. Responders were defined as patients who required no additional rescue medication within 30 minutes of the initial dose of IM ziprasidone for agitation. Nonresponders were defined as patients who required additional rescue medications for agitation after the initial dose of IM ziprasidone. A 30-minute time window was selected to reflect the need for emergent agitation control in a pediatric ED and is supported by previous studies showing ziprasidone's effect within 30 minutes. 7, 11 Secondary outcomes included adjunctive medications given to nonresponders, time between medications given to nonresponders, and adverse events associated with ziprasidone administration.
Patient Selection and Data Collection
Patients greater than 1 year and less than 18 years who received at least 1 dose of IM ziprasidone between July 1, 2007, and February 1, 2015, in the pediatric ED were evaluated. Patients were excluded from the study if they did not meet the age requirements. The following data were collected-age, gender, weight, chief complaint (medical or psychiatric), psychiatric history (collected only if patient had a psychiatric chief complaint), the initial dose of ziprasidone administered, and whether additional rescue medication was given to the patient within 30 minutes of receiving their initial ziprasidone dose. If additional doses of ziprasidone were administered within 30 minutes, the additional dose and the total dose of ziprasidone administered were recorded. Notably, no institutional ziprasidone dosing guidance or protocol for acute agitation existed at the time this study was conducted. Instead, ziprasidone dosing and frequency were based on physician judgment. Data on breathing difficulties leading to intubation and EPS, including acute dystonia, pseudoparkinsonism, tardive dyskinesia, or akathisia, were also collected. Electrocardiogram (ECG) results were not collected, as use of ECGs after atypical antipsychotic administration is not a standard ED practice.
Data Analysis
Since variables were descriptive and continuous, a 2-tailed Student t test with unequal variance was performed to determine whether there was statistical significance. An a level of less than 0.05 was chosen to determine statistical significance.
Results
Forty patients received a total of 50 doses of IM ziprasidone in the pediatric ED between July 1, 2007, and February 1, 2015. The mean age of patients receiving a dose of IM ziprasidone was 11.8 years with a range of 5 to 17 years.
The majority of patients were male with a psychiatric chief complaint (Table 1 ). There were no statistically significant differences in demographic characteristics between responders and nonresponders. Approximately two-thirds of all patients who presented with a psychiatric chief complaint had a diagnosis of attention-deficit/hyperactivity disorder (n ¼ 22, 61%) and one-third had a diagnosis of autism spectrum disorder (n ¼ 12, 33%). Other diagnoses included posttraumatic stress disorder, bipolar disorder, and intellectual disabilities.
Primary End Point
Ziprasidone was the first-line agent in all 40 patients for acute agitation. The majority of patients responded to the initial dose of ziprasidone (n ¼ 27, 68%; Table 2 ). The mean initial dose of ziprasidone was 0.19 + 0.1 mg/kg in the responders and 0.13 + 0.06 mg/kg in the nonresponders (P ¼ 0.03). Ten of 13 patients in the nonresponder groups required 1 additional dose of IM ziprasidone. As a result, the total mean ziprasidone dose given to nonresponders to achieve control was 0.23 + 0.14 mg/kg. Single doses of ziprasidone ranged from 2.5 to 20 mg. 
Secondary End Points
Nonresponders who required 1 additional dose of IM ziprasidone had a mean time of 18 minutes from the first to last dose of ziprasidone (range: 5-30 minutes). Notably, there are no repeat dosing recommendations for acute agitation in pediatrics. 5 Four patients also received adjunctive medications including an alternative antipsychotic, an antihistamine, and benzodiazepines ( Table 3 ). All of these medications were received after the initial ziprasidone dose.
From a safety perspective, no patients experienced respiratory depression requiring intervention. Two patients experienced potential EPS; however, the first patient experienced dystonic movements prior to being administered ziprasidone, while the second patient had baseline facial twitching. Any exacerbation of symptoms caused by the ziprasidone was not documented.
Discussion
Ziprasidone was the first atypical antipsychotic medication approved in the United States for IM use, gaining the Food and Drug Administration approval for rapid control of agitation and psychotic symptoms in 2002. Since its approval, no publications have identified an effective mg/kg ziprasidone dosing scheme for pediatric patients, despite the dose-response relationship shown in the adult literature.
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The evidence for IM ziprasidone in pediatrics is minimal. Only 4 relatively small studies and 1 case series have retrospectively looked at the safety and efficacy of IM ziprasidone in the management of acute agitation in pediatrics. [6] [7] [8] [9] [10] Staller conducted a retrospective review of 49 patients, 8 to 16 years of age, who received 10 or 20 mg of IM ziprasidone. 6 Effectiveness was evaluated by whether readministration was necessary within 4 hours. Only 1 patient required repeat dosing, leading the author to conclude that IM ziprasidone was well tolerated and effective. Barzman et al further supported this conclusion through their retrospective review of patients 5-to 19-years-old who received IM ziprasidone for impulsivity and agitation. 7 In 59 patients who received 77 doses of ziprasidone, a statistically significant decrease in the mean Behavioral Activity Rating Scale (BARS) after 10 or 20 mg of IM ziprasidone was noted. When IM ziprasidone at 10 or 20 mg was compared against IM olanzapine, or the combination of haloperidol and lorazepam, pediatric studies found equivalent efficacy. 8, 9 Despite the presented data on the safety and efficacy of IM ziprasidone in pediatric psychiatry units, no evidence exists on the utilization of ziprasidone in the pediatric ED.
Given this lack of guidance and the absolute recommended 10 or 20 mg dosing of ziprasidone, providers may be more tentative in their dosing in pediatric patients, thus resulting in ineffective control at 30 minutes. This is more challenging in the ED, compared to pediatric psychiatric facilities, as resources are limited and often highly strained depending on patient volume and acuity. This is the first study that examines IM ziprasidone for pediatric acute agitation in the ED. Data suggest that an initial ziprasidone dose of 0.2 mg/kg may be more effective at obtaining control of acute agitation within 30 minutes, as responders received a statistically significant higher mean initial dose of ziprasidone at 0.19 + 0.1 mg/kg compared to nonresponders at 0.13 + 0.06 mg/kg (P ¼ 0.03). The importance of the characterization of this single mg/kg dose cannot be overlooked, as it may help obviate the need for subsequent medication administrations, thereby minimizing agitating encounters between the patient and exposure to additional medications and their side effects. Since a maximum initial IM ziprasidone dose of 20 mg is recommended in adults, pediatric providers should also limit their single mg/kg dosing to 20 mg. The maximum total dose of ziprasidone administered in this study was 20 mg.
Limitations
There were several limitations to this study. Its retrospective design limited chart abstraction of additional information, such as the use of alternative psychosocial techniques and physical restraints for acute agitation management. In addition, the patient's home medications and experience with atypical antipsychotics were not collected, which may have altered the ED provider's dose selection and patient response.
This study replicated the methodology proposed by Staller, and a 30-minute assessment time was chosen to reflect the emergent need for behavioral control in the ED and the onset of ziprasidone's effectiveness. 6, 7, 11 However, the assessment time may have been too short to evaluate the true maximum efficacy of ziprasidone. Due to the retrospective nature of the study and inconsistent documentation of response, a valid scale for the assessment of agitation, such as the BARS, was not applied. Instead, efficacy was based on the subjective assessment of the ED provider, which was felt to be more reflective of current practice.
Notably, no patients received ECGs to evaluate for QT prolongation, a known potential effect of this medication. The obtainment of an ECG before or immediately after administration of ziprasidone is not typically done in the ED, especially in acutely agitated patients. As a result, ziprasidone's adverse effect of QT prolongation was not assessed in this study.
Conclusion
In summary, an initial dose of 0.2 mg/kg of IM ziprasidone may be considered when managing acutely agitated pediatric patients in the ED in order to achieve acute control and minimize the need for additional medication. A total dose of 20 mg 
